Abstract
Neonatal thrombocytopenia affects 20-40% of the infants in intensive care units. The frequency of neonatal alloimmune thrombocytopenia (NAIT) is estimated at 1/1500 to 1/5000 live births. The risk of morbidity is significant with 20% neurological sequelae and the death rate is estimated at 10% of affected infants. During recent years considerable efforts have been made to prevent fetal bleeding and to avoid birth trauma, which have significantly changed the natural history of NAIT.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antigens, Human Platelet / immunology
-
Blood Component Transfusion
-
Blood Platelets / immunology
-
Blood Transfusion, Intrauterine
-
Female
-
Fetal Blood / immunology
-
Fetal Diseases / diagnosis
-
Fetal Diseases / epidemiology
-
Fetal Diseases / immunology*
-
Fetal Diseases / therapy
-
Hemorrhage / prevention & control
-
Histocompatibility Testing
-
Humans
-
Immunity, Maternally-Acquired*
-
Incidence
-
Infant, Newborn
-
Isoantibodies / immunology*
-
Platelet Count
-
Platelet Transfusion
-
Pregnancy
-
Pregnancy Outcome
-
Prenatal Diagnosis
-
Risk Factors
-
Thrombocytopenia / congenital*
-
Thrombocytopenia / diagnosis
-
Thrombocytopenia / epidemiology
-
Thrombocytopenia / immunology
-
Thrombocytopenia / therapy
-
Treatment Outcome
Substances
-
Antigens, Human Platelet
-
Isoantibodies